China's NMPA Strengthens Contract Manufacturing Oversight, Sets New Quality Obligations for MAHs and CMOs
Key Insights
China's NMPA has published new rules strengthening supervision of contract manufacturers, requiring joint responsibility for drug quality and safety between marketing authorization holders and manufacturers.
Contract manufacturers must now establish evaluation mechanisms for MAHs, assessing qualifications, quality management capabilities, and product risk factors before signing deals.
For high-risk sterile drugs (search), MAHs must conduct annual on-site supervision of validation activities, and either party must have at least three years of commercial sterile manufacturing experience.
China's National Medical Products Administration (search) (NMPA) has published comprehensive new rules strengthening the supervision and administration of contract manufacturers, marking a significant regulatory shift that clarifies obligations and responsibilities across pharmaceutical supply chains. The document, published last week, aims to ensure marketing authorization holders (MAHs) and contract manufacturers jointly guarantee drug quality and safety.
The regulatory framework is divided into two main sections: one addressing contract manufacturers' responsibilities and another focused on supervising outsourced production. Together, they establish a more rigorous oversight structure for China's rapidly expanding pharmaceutical contract manufacturing sector.
New Evaluation Requirements for Contract Manufacturers
Under the new rules, contract manufacturers must establish a formal mechanism for evaluating MAHs and their products before entering into any agreement. The evaluation must assess the MAH's qualifications, quality management capabilities, the risk factors of proposed products, and the feasibility of accepting technical transfer and co-line production.
MAHs are required to cooperate actively and truthfully with the evaluation team. Companies can only sign manufacturing deals after the MAH passes this evaluation process. NMPA has signaled a preference for contract manufacturers to prioritize cooperation with MAHs "that possess independent research and development management capabilities and master of key process technologies of the contracted products."
Risk Management and Technical Transfer Obligations
The document outlines specific tasks that contract manufacturers must perform during technology transfer, including validation of facilities and equipment, analysis of tech transfer data, and formulation of technical documents. Both MAHs and contract manufacturers are expected to strengthen risk identification, communication, and analysis when transferring products for outsourcing.
If elements such as software, hardware, and quality management make technology transfer difficult or drug quality risks arise, partners must communicate and act immediately. NMPA expects companies to terminate projects when risks are "difficult to control effectively."
Heightened Requirements for High-Risk Products
For high-risk products such as sterile drugs (search), NMPA has imposed particularly stringent requirements. MAHs must supervise validation activities during on-site inspections at least once a year, with supervision covering sterilization process validation and aseptic process simulation tests.
Additionally, either the MAH or the contract manufacturer must have at least three years of commercial experience manufacturing sterile drugs (search) of the same dosage form, establishing a baseline competency requirement for parties involved in sterile manufacturing.
Multi-Site Manufacturing and Quality Consistency
When MAHs outsource production of a drug to multiple companies, they must ensure all partners follow the approved manufacturing process. Where differences in conditions exist between sites, contract manufacturers must cooperate with MAHs to conduct comparative analyses, carry out risk assessments on the differences, and formulate risk prevention and control measures. MAHs are also required to compare quality across manufacturing sites regularly.
Implementation Timeline and Enforcement
NMPA has asked provincial drug regulatory authorities to urge MAHs and contract manufacturers to conduct comprehensive self-inspections aligned with the new requirements. Companies that identify situations inconsistent with the requirements must rectify the issues within one year. For fixes requiring longer than one year, companies must clearly state the reasons for the extended timeline.
The new rules represent NMPA's latest effort to enhance pharmaceutical quality oversight as China continues to grow as a major source of new drug candidates, driven in part by the speed at which Chinese biotechs can advance assets to clinical proof of concept.